Date Filed | Type | Description |
10/06/2023 |
4
| SAPIRSTEIN JAMES (President and CEO) has filed a Form 4 on First Wave BioPharma, Inc.
Txns:
| Sold 2,764 shares
@ $0.29, valued at
$801.6 |
|
07/05/2023 |
4
| SAPIRSTEIN JAMES (President and CEO) has filed a Form 4 on First Wave BioPharma, Inc.
Txns:
| Sold 3,349 shares
@ $1.54, valued at
$5.2k
|
|
06/01/2023 |
4
| SAPIRSTEIN JAMES (Director) has filed a Form 4 on Blue Water Biotech, Inc.
Txns:
| Granted 6,360 shares
@ $0 |
|
04/05/2023 |
4
| SAPIRSTEIN JAMES (President and CEO) has filed a Form 4 on First Wave BioPharma, Inc.
Txns:
| Sold 3,347 shares
@ $2.5, valued at
$8.4k
|
|
04/04/2023 |
4
| SAPIRSTEIN JAMES (Director) has filed a Form 4 on Enochian Biosciences Inc
Txns:
| Granted 64,655 options to buy
@ $1.16, valued at
$75k
|
|
01/17/2023 |
3
| SAPIRSTEIN JAMES (Director) has filed a Form 3 on ZyVersa Therapeutics, Inc. |
01/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/27/2022 |
4
| SAPIRSTEIN JAMES (Director) has filed a Form 4 on Blue Water Vaccines Inc.
Txns:
| Granted 50,575 options
@ $6.45, valued at
$326.2k
|
|
02/23/2022 |
3
| SAPIRSTEIN JAMES (Director) has filed a Form 3 on Blue Water Vaccines Inc. |
01/03/2022 |
4
| SAPIRSTEIN JAMES (PRES, CEO & CHAIRMAN OF BOARD) has filed a Form 4 on First Wave BioPharma, Inc.
Txns:
| Granted 150,000 options to buy
@ $1.45, valued at
$217.5k
|
|
07/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/23/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/11/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/15/2020 |
3
| SAPIRSTEIN JAMES (Director) has filed a Form 3 on Blue Water Acquisition Corp. |
09/10/2020 |
3
| SAPIRSTEIN JAMES (Interim Chief Executive Office) has filed a Form 3 on MARIZYME INC |
07/20/2020 |
4
| SAPIRSTEIN JAMES (PRESIDENT AND CEO) has filed a Form 4 on AzurRx BioPharma, Inc.
Txns:
| Granted 1,200,000 options to buy
@ $0.85, valued at
$1M
Granted 13 convertible preferred
@ $0 Granted 64,935 options to buy
@ $0.85, valued at
$55.2k
|
|
10/10/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/10/2019 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
08/26/2019 |
4
| SAPIRSTEIN JAMES (Director) has filed a Form 4 on Enochian Biosciences Inc
Txns:
| Granted 9,173 options to buy
@ $6.25, valued at
$57.3k
|
|
09/27/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
09/04/2018 |
3
| SAPIRSTEIN JAMES (Director) has filed a Form 3 on Enochian Biosciences Inc |
01/05/2018 |
4
| SAPIRSTEIN JAMES (CEO) has filed a Form 4 on ContraVir Pharmaceuticals, Inc.
Txns:
| Granted 322,092 shares
@ $0 |
|
12/12/2017 |
4
| SAPIRSTEIN JAMES (Director) has filed a Form 4 on RespireRx Pharmaceuticals Inc.
Txns:
| Acquired 38,114 options to buy
@ $1.45, valued at
$55.3k
|
|
07/07/2017 |
4
| SAPIRSTEIN JAMES (CEO) has filed a Form 4 on ContraVir Pharmaceuticals, Inc.
Txns:
| Granted 141,061 shares
@ $0 |
|
07/05/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
03/07/2017 |
4
| SAPIRSTEIN JAMES (CEO) has filed a Form 4 on ContraVir Pharmaceuticals, Inc. |
02/15/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
02/15/2017 |
3
| Form 3 - Initial statement of beneficial ownership of securities |
01/20/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
10/31/2016 |
4
| SAPIRSTEIN JAMES (CEO) has filed a Form 4 on ContraVir Pharmaceuticals, Inc. |
06/14/2016 |
4
| SAPIRSTEIN JAMES (CEO) has filed a Form 4 on ContraVir Pharmaceuticals, Inc.
Txns:
| Granted 500,000 options
@ $0.99, valued at
$495k
|
|
04/04/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
02/18/2016 |
4
| SAPIRSTEIN JAMES (CEO) has filed a Form 4 on ContraVir Pharmaceuticals, Inc. |
11/09/2012 |
4
| SAPIRSTEIN JAMES (CEO) has filed a Form 4 on Alliqua, Inc.
Txns:
| Granted 9,286,408 options to buy
@ $0.1, valued at
$928.6k
Granted 3,095,469 options to buy
@ $0 |
|